Compare SSM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSM | NRSN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Germany | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.6M |
| IPO Year | 2021 | 2021 |
| Metric | SSM | NRSN |
|---|---|---|
| Price | $1.13 | $2.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $78.50 |
| AVG Volume (30 Days) | ★ 2.2M | 17.8K |
| Earning Date | 11-19-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,447,140.40 | N/A |
| Revenue Next Year | $48.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.25 |
| 52 Week High | $10.54 | $7.50 |
| Indicator | SSM | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 37.25 |
| Support Level | $1.05 | $0.63 |
| Resistance Level | $2.58 | $7.50 |
| Average True Range (ATR) | 0.12 | 0.37 |
| MACD | 0.04 | -0.24 |
| Stochastic Oscillator | 7.95 | 14.04 |
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and services include Complete Solar Solutions, Solar Charge Controllers, Solar Modules, Data Services, and Engineering Services. The company's single business segment manages the financing, research and development, and product commercialization.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.